Shares of Forward Pharma A/S (NASDAQ:FWP) have been given a consensus rating of “Hold” by the six research firms that are presently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $24.00.

A number of analysts have recently weighed in on the stock. Jefferies Group LLC set a $22.00 price objective on shares of Forward Pharma A/S and gave the stock a “hold” rating in a research note on Tuesday, April 18th. JMP Securities cut shares of Forward Pharma A/S from an “outperform” rating to a “market perform” rating in a research note on Monday, April 3rd. BidaskClub upgraded shares of Forward Pharma A/S from a “sell” rating to a “hold” rating in a research note on Tuesday, June 20th. ValuEngine upgraded shares of Forward Pharma A/S from a “sell” rating to a “hold” rating in a research note on Saturday, June 17th. Finally, Zacks Investment Research upgraded shares of Forward Pharma A/S from a “hold” rating to a “buy” rating and set a $22.00 price objective for the company in a research note on Wednesday, April 5th.

COPYRIGHT VIOLATION WARNING: “Forward Pharma A/S (NASDAQ:FWP) Receives Consensus Rating of “Hold” from Analysts” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/07/17/forward-pharma-as-nasdaqfwp-receives-consensus-rating-of-hold-from-analysts.html.

Institutional investors have recently made changes to their positions in the company. NJ State Employees Deferred Compensation Plan acquired a new stake in shares of Forward Pharma A/S during the first quarter valued at about $323,000. Eqis Capital Management Inc. acquired a new stake in shares of Forward Pharma A/S during the first quarter valued at about $346,000. MARSHALL WACE ASIA Ltd acquired a new stake in shares of Forward Pharma A/S during the first quarter valued at about $612,000. Marshall Wace North America L.P. acquired a new stake in shares of Forward Pharma A/S during the first quarter valued at about $612,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Forward Pharma A/S during the first quarter valued at about $269,000. 22.32% of the stock is currently owned by institutional investors and hedge funds.

Forward Pharma A/S (FWP) traded up 0.77% during midday trading on Monday, reaching $21.07. 6,816 shares of the company were exchanged. Forward Pharma A/S has a one year low of $14.89 and a one year high of $33.00.

Forward Pharma A/S Company Profile

Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.

Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.